Insider Selling: AngioDynamics (NASDAQ:ANGO) CFO Sells $20,932.40 in Stock

Key Points

• AngioDynamics CFO Stephen Trowbridge sold 1,720 shares at an average price of $12.17, generating $20,932.40 and reducing his ownership by 0.56% to 304,076 shares.
• ANGO shares fell 2.9% to $11.99, while the company reported a quarterly loss of $0.04 per share—better than the $0.11 consensus loss—and revenue of $80.92 million.
• Analyst views remain mixed, but the stock carries a “Moderate Buy” consensus rating with a $19.00 average price target; institutional investors own approximately 89.43% of the shares.

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) CFO Stephen Trowbridge sold 1,720 shares of AngioDynamics stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $12.17, for a total value of $20,932.40. Following the completion of the sale, the chief financial officer owned 304,076 shares of the company's stock, valued at approximately $3,700,604.92. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

AngioDynamics Stock Down 2.9%

ANGO traded down $0.36 during trading on Friday, hitting $11.99. The company had a trading volume of 475,817 shares, compared to its average volume of 531,842. The company has a market capitalization of $504.18 million, a PE ratio of -15.37 and a beta of 0.30. The firm's 50-day moving average price is $14.26 and its 200 day moving average price is $12.46. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. The firm had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Sell-side analysts forecast that AngioDynamics, Inc. will post -0.26 earnings per share for the current year.

Analysts Set New Price Targets

ANGO has been the subject of several analyst reports. HC Wainwright lowered their price target on shares of AngioDynamics from $19.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, October 13th. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price objective on shares of AngioDynamics in a research note on Friday, October 9th. Wall Street Zen lowered shares of AngioDynamics from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. Zacks Research raised AngioDynamics from a "strong sell" rating to a "hold" rating in a research report on Monday, October 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Hedge Funds Weigh In On AngioDynamics

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of AngioDynamics during the second quarter worth $49,480,000. Weber Capital Management LLC ADV acquired a new position in shares of AngioDynamics in the second quarter valued at approximately $17,649,392. Bastion Asset Management Inc. boosted its position in shares of AngioDynamics by 17.4% in the first quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier's stock worth $14,107,000 after acquiring an additional 194,822 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in AngioDynamics by 3.5% during the first quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier's stock worth $10,786,000 after buying an additional 32,476 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in AngioDynamics by 0.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier's stock valued at $8,624,000 after purchasing an additional 5,509 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company's portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.